Last edition
News about "Jacob Van Naarden"
CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU
CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.
Jacob Van Naarden | 29/06/2026 | By News Bureau
Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL
Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.
Jacob Van Naarden | 15/06/2026 | By News Bureau
Lilly's Retevmo Shows Significant Benefit in Early-Stage RET+ Lung Cancer in Phase III Trial
LIBRETTO-432 study demonstrates statistically significant improvement in event-free survival as adjuvant therapy for stage II–IIIA RET fusion-positive NSCLC.
Jacob Van Naarden | 17/02/2026 | By News Bureau | 272
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
Jacob Van Naarden | 10/09/2025 | By Dineshwori | 171
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy